The HLA-B27 test checks whether a person carries an HLA-B allele group strongly associated with axial spondyloarthritis, including ankylosing spondylitis. It is a supporting test, not a yes-or-no diagnosis. A positive result makes axial spondyloarthritis more likely when someone has inflammatory back pain, sacroiliac joint inflammation, uveitis, psoriasis, inflammatory bowel disease, enthesitis, or a relevant family history. Most HLA-B27-positive people never develop ankylosing spondylitis, and some people with confirmed disease are HLA-B27 negative. The result therefore has to be combined with symptoms, physical examination, C-reactive protein or erythrocyte sedimentation rate, and imaging—often an X-ray or MRI of the sacroiliac joints. Testing requires a blood sample or sometimes a cheek swab, with no fasting or special preparation. HLA-B27 is inherited and normally remains unchanged for life, so a valid result usually needs to be obtained only once.
- HLA-B27 positive means increased susceptibility to axial spondyloarthritis, not a confirmed diagnosis.
- HLA-B27 negative does not rule out ankylosing spondylitis or non-radiographic axial spondyloarthritis.
- The test is most useful when inflammatory back pain or related features already create clinical suspicion.
- There is no high, low, or normal range; the report is usually positive/negative or allele detected/not detected.
- A painful red light-sensitive eye can be acute anterior uveitis and needs prompt eye assessment.
Table of Contents
- What HLA-B27 Is
- When HLA-B27 Testing Helps
- How the Test Is Done
- What a Positive HLA-B27 Result Means
- What a Negative Result Means
- How the Result Fits With Symptoms and Imaging
- Other Conditions Associated With HLA-B27
- Limitations and Next Steps
What HLA-B27 Is
HLA-B27 is a family of closely related alleles at the HLA-B gene. HLA-B is a class I human leukocyte antigen gene within the major histocompatibility complex on chromosome 6. It produces a cell-surface molecule that presents short peptide fragments to CD8 T cells and also interacts with natural killer cell receptors.
Everyone normally has two HLA-B alleles, one inherited from each biological parent. A person is called HLA-B27 positive when at least one inherited allele belongs to the B27 group. The most common subtype in many populations is HLA-B27:05, but numerous subtypes exist, including HLA-B27:02, *27:04, and others. Subtype frequencies vary by ancestry, and not every subtype appears to carry identical disease risk.
HLA-B27 is a normal immune-system variant. It is not a damaged gene, infection, inflammatory marker, or proof that the spine is injured. The association with spondyloarthritis probably reflects several biological effects, which may include:
- Presentation of particular self or microbial peptides to T cells
- Misfolding of the HLA-B27 protein and cellular stress responses
- Formation of unusual HLA-B27 structures at the cell surface
- Effects on the gut microbiome and mucosal immunity
- Interactions with other immune genes and environmental triggers
No single mechanism fully explains the disease. HLA-B27 is the strongest common genetic association, but axial spondyloarthritis is polygenic. ERAP1 and other immune-related genes contribute, and genetics interacts with sex, microbiome, smoking, mechanical stress, and other factors.
The proportion of people who carry HLA-B27 differs greatly around the world. It is relatively common in some northern European and Indigenous populations and uncommon in others. Disease associations also vary by population, so a result cannot be interpreted with one universal percentage.
A complete HLA-B genetic test may report the exact B27 subtype along with the person’s other HLA-B allele. A focused clinical test often reports only positive or negative because that is enough for the diagnostic question.
When HLA-B27 Testing Helps
HLA-B27 testing is most informative when symptoms suggest a spondyloarthritis but the diagnosis is not yet clear. Testing healthy people without symptoms usually creates more uncertainty than benefit because most positive carriers never develop disease.
Features that may justify testing include chronic back pain beginning before age 45, especially when it has an inflammatory pattern. Inflammatory back pain often:
- Begins gradually rather than after one clear injury
- Persists for at least three months
- Improves with movement or exercise
- Does not improve, or improves less, with rest
- Causes prolonged morning stiffness
- Wakes the person during the second half of the night
- Produces alternating buttock pain
None of these features is specific on its own. Mechanical back pain is far more common, and some people with axial spondyloarthritis describe mixed patterns.
Testing can also help when back or joint symptoms occur with:
- Acute anterior uveitis
- Psoriasis
- Crohn disease or ulcerative colitis
- Heel pain from enthesitis
- Dactylitis, sometimes called a sausage digit
- Peripheral arthritis, especially in the lower limbs
- A close relative with axial spondyloarthritis
- A strong response to a nonsteroidal anti-inflammatory drug
- Elevated inflammatory markers without another explanation
- Sacroiliac joint changes that are suspicious but not definitive
HLA-B27 may be ordered by a rheumatologist, primary care clinician, ophthalmologist, gastroenterologist, dermatologist, or emergency clinician. Recurrent unilateral acute anterior uveitis can be the first clue to an undiagnosed spondyloarthritis, even before persistent back symptoms become prominent.
The test is not a population screening test for children of affected parents. A positive child may never become ill, and there is no preventive medicine given solely for carrying the allele. Testing an asymptomatic relative generally does not replace attention to future symptoms.
HLA-B27 is also not useful for monitoring treatment. The result stays positive or negative regardless of disease activity. C-reactive protein, symptoms, examination, imaging, and functional measures are used to assess activity and response.
How the Test Is Done
Most laboratories use a blood sample. Some molecular tests can use a cheek swab. No fasting is needed, and anti-inflammatory or biologic medicines do not change the inherited result.
Two broad approaches are used:
Cell-based antigen testing
Flow cytometry uses an antibody that recognizes the HLA-B27 antigen on white blood cells. It can provide a rapid positive or negative answer. Rare cross-reactivity with other HLA-B antigens can cause an uncertain or false-positive pattern, depending on the antibody reagent and population.
DNA-based testing
Molecular methods identify HLA-B27-associated DNA sequences. These include sequence-specific primer PCR, probe-based testing, Sanger sequencing, and next-generation sequencing. DNA methods can confirm a questionable antigen result and may identify the exact subtype.
A report may say:
- HLA-B27 positive
- HLA-B27 antigen detected
- HLA-B27 allele detected
- HLA-B*27:05 present
- HLA-B27 negative or not detected
There is no concentration or reference interval. The test is categorical. “Positive” does not mean a high amount of HLA-B27, and repeat levels cannot track inflammation.
Results are usually available within days, although timing varies. The test can be performed at any age, but its clinical value depends on the pretest probability created by symptoms and findings.
A valid result generally does not need repeating. Repeat testing may be considered when:
- A flow-cytometry result is weak or indeterminate
- The clinical picture strongly conflicts with the result
- A low-resolution or research result needs clinical confirmation
- The specimen identity is in doubt
- The person has received an allogeneic stem-cell transplant
After donor stem-cell transplantation, blood leukocytes carry the donor’s HLA type. A blood HLA-B27 result may therefore describe the donor, not the recipient’s inherited genotype. The laboratory needs to know the transplant history and may choose a different specimen if the recipient genotype matters.
What a Positive HLA-B27 Result Means
A positive result increases the likelihood of axial spondyloarthritis when the clinical pattern already fits. Its effect depends on the person’s background risk.
For example, a healthy person with no inflammatory symptoms has a low pretest probability. A positive result raises genetic susceptibility but still leaves disease unlikely. In contrast, a person under age 45 with chronic inflammatory back pain, recurrent uveitis, and sacroiliac inflammation has a much higher pretest probability; HLA-B27 positivity adds meaningful support.
In many European ancestry cohorts, a large majority of people with radiographic ankylosing spondylitis are HLA-B27 positive. The percentage is lower in some other populations and in non-radiographic axial spondyloarthritis. The allele’s frequency among healthy controls also differs by ancestry. These differences are why a laboratory result should not be converted into a universal disease probability.
A positive result can support:
- Referral to rheumatology
- A decision to obtain sacroiliac joint imaging
- Recognition that recurrent uveitis may be part of a systemic condition
- Classification of axial spondyloarthritis in an appropriate clinical setting
- A stronger family-history assessment
It does not show whether structural damage is present. It cannot distinguish non-radiographic axial spondyloarthritis from ankylosing spondylitis. The difference depends mainly on whether definite sacroiliitis is visible on plain radiographs, not on HLA status.
HLA-B27 positivity may be associated at the group level with earlier onset, uveitis, family clustering, or particular disease features, but it does not predict one individual’s course with certainty. It cannot tell whether spinal fusion will occur or which biologic drug will work.
A positive result should not lead to treatment without clinical evidence of disease. Nonsteroidal anti-inflammatory drugs, biologics, and other therapies have risks and are prescribed for active disease, not for genotype alone.
What a Negative Result Means
A negative HLA-B27 result lowers the probability of axial spondyloarthritis but does not exclude it. The strength of that reduction depends on ancestry, disease subtype, and the rest of the clinical picture.
HLA-B27-negative axial spondyloarthritis is well recognized. It may be more common among patients with psoriasis-associated axial disease, inflammatory bowel disease, or certain ancestry backgrounds. Women and people with non-radiographic disease may also experience delayed recognition when clinicians over-rely on a negative test.
A negative result should not end the evaluation when there is:
- MRI evidence of active sacroiliitis
- Definite radiographic sacroiliitis
- Persistent inflammatory back pain with several spondyloarthritis features
- Recurrent acute anterior uveitis
- Psoriasis or inflammatory bowel disease plus suggestive axial symptoms
- Elevated inflammatory markers and no better explanation
- A strong family history and compatible examination
The result can be falsely negative if the assay does not detect a rare subtype, the sample is inadequate, or the wrong specimen is used after stem-cell transplantation. Modern clinical assays detect common HLA-B27 variants well, so analytical false negatives are uncommon but possible.
A negative result does not indicate that the immune system is normal or abnormal. It does not rule out rheumatoid arthritis, lupus, fibromyalgia, degenerative disc disease, infection, cancer, or other causes of back pain. Those conditions require separate assessment.
It is also important not to interpret “HLA-B27 not detected” as “HLA-B gene absent.” The person still carries two HLA-B alleles; neither belongs to the tested B27 group.
How the Result Fits With Symptoms and Imaging
Axial spondyloarthritis is diagnosed from a pattern, not one biomarker. The clinician combines history, examination, laboratory tests, and imaging while excluding better explanations.
Plain pelvic radiographs can show erosions, sclerosis, joint-space change, or ankylosis in the sacroiliac joints. When definite radiographic sacroiliitis is present with the clinical syndrome, the condition is often called radiographic axial spondyloarthritis or ankylosing spondylitis.
MRI can detect bone marrow edema and other inflammatory changes before structural damage is visible on X-ray. However, MRI findings are not perfectly specific. Mechanical stress, childbirth, athletics, osteoarthritis, infection, and normal variation can create findings that resemble inflammation. Images should be interpreted by experienced clinicians in context.
Inflammatory markers add information but can be normal. C-reactive protein and erythrocyte sedimentation rate are not elevated in every patient, and a normal result does not rule out active disease.
Classification criteria are designed primarily to create comparable research groups. They can guide thinking but should not be used as a mechanical diagnostic checklist. A person may meet classification criteria without having the disease, or have the disease without meeting criteria at one point in time.
A balanced interpretation may look like this:
| Clinical situation | Meaning of the result | Usual next step |
|---|---|---|
| No symptoms, HLA-B27 positive | Genetic susceptibility only; disease is not diagnosed | No imaging or treatment solely because of the allele |
| Inflammatory back pain, HLA-B27 positive | Axial spondyloarthritis becomes more likely | Clinical assessment and appropriate imaging |
| Inflammatory back pain, HLA-B27 negative | Probability falls but remains meaningful | Review other features, markers, and imaging |
| Mechanical pain pattern, HLA-B27 positive | The allele may be incidental | Evaluate mechanical and other common causes |
Treatment decisions depend on active symptoms and objective disease. Exercise and physical therapy are central. Nonsteroidal anti-inflammatory drugs, tumor necrosis factor inhibitors, interleukin-17 inhibitors, Janus kinase inhibitors, or other strategies may be considered according to diagnosis, severity, comorbidities, and guidelines. HLA-B27 itself is not a treatment target in routine care.
Other Conditions Associated With HLA-B27
HLA-B27 is associated with a family of related inflammatory disorders rather than ankylosing spondylitis alone.
Acute anterior uveitis often causes sudden eye pain, redness around the iris, light sensitivity, blurred vision, and tearing. It is usually unilateral and can recur in the other eye. Eye symptoms require prompt ophthalmic evaluation because untreated inflammation can threaten vision.
Reactive arthritis can develop after certain gastrointestinal or genitourinary infections. HLA-B27 may be associated with more persistent or axial features, but testing does not identify the triggering organism and is not required for every case.
Psoriatic arthritis can affect the spine and sacroiliac joints. HLA-B27 is more common in some patients with axial involvement, yet many are negative. The pattern can differ from classic ankylosing spondylitis.
Inflammatory bowel disease-associated arthritis can involve peripheral joints or the axial skeleton. HLA-B27 may support an axial phenotype but cannot determine whether bowel inflammation is present.
Enthesitis-related arthritis is a juvenile idiopathic arthritis category involving entheses and joints, often in older children or adolescents. HLA-B27 may contribute to classification and prognosis in the right pediatric setting, but age-specific evaluation is essential.
HLA-B27 has also been studied in rare cardiac, neurologic, and infectious contexts. These associations generally do not justify stand-alone screening. A test ordered for back pain should not be interpreted as a broad prediction of every reported HLA-B27-related condition.
Limitations and Next Steps
The main limitation is probabilistic interpretation. HLA-B27 has no universal positive predictive value because carrier frequency and disease prevalence vary across populations. Referral patterns also affect published estimates.
Other limitations include:
- Different assays may report antigen group or exact allele subtype
- Rare cross-reactivity can affect cell-based testing
- Genetic ancestry may be more complex than a checkbox on a form
- HLA-B27 does not measure current inflammation or structural damage
- Imaging can be overread or underread
- Normal inflammatory markers do not exclude disease
- Classification criteria are not identical to clinical diagnosis
After receiving a result, ask:
- Does the pain pattern sound inflammatory or mechanical?
- Were psoriasis, uveitis, bowel symptoms, enthesitis, and family history reviewed?
- Is sacroiliac imaging needed, and should it be X-ray or MRI?
- Are inflammatory markers useful in this situation?
- Could another diagnosis better explain the symptoms?
- Does the test identify only HLA-B27 or the exact subtype?
- Has a stem-cell transplant affected the specimen source?
Seek prompt care for a painful red light-sensitive eye. Emergency assessment is also appropriate for new leg weakness, saddle numbness, loss of bladder or bowel control, fever with severe back pain, or other neurologic or infection warning signs; these are not routine features to explain with HLA-B27.
For persistent inflammatory back symptoms, a rheumatology assessment can be appropriate even after a negative result. For an incidental positive result without symptoms, routine scans, repeated blood tests, and preventive medication are generally not warranted.
Keep the original laboratory report. HLA-B27 status normally remains stable and need not be repeated for disease monitoring. The most accurate interpretation is simple: HLA-B27 changes the probability of spondyloarthritis, while the diagnosis comes from the entire clinical picture.
Diagnostic delay remains common because early axial spondyloarthritis may not appear on plain radiographs and because symptoms are often attributed to strain, posture, or nonspecific chronic pain. The disease can occur in all sexes. Women and HLA-B27-negative patients may have less classic radiographic patterns, more peripheral symptoms, or longer delays before referral. A negative test should not be used as a shortcut to dismiss persistent inflammatory features.
Physical examination may assess spinal mobility, chest expansion, sacroiliac provocation, hip movement, entheses, skin, nails, and swollen joints. Examination can be normal early in disease. The clinician may also review whether pain improves after a full therapeutic trial of a nonsteroidal anti-inflammatory drug, while considering gastrointestinal, kidney, cardiovascular, and pregnancy risks.
MRI interpretation deserves particular caution. Bone marrow edema must occur in a distribution and clinical setting consistent with sacroiliitis. Small focal lesions can occur after running, military training, heavy physical work, or pregnancy. Structural lesions such as erosions, fat metaplasia, or ankylosis can strengthen interpretation, but no isolated MRI feature should replace expert review.
Family members sometimes ask whether HLA-B27 testing can predict a child’s future. The allele is inherited in an autosomal codominant manner, so a positive parent can pass it on, but penetrance is low. Testing an asymptomatic child rarely changes activity, sports, diet, or medical care. A more useful plan is awareness of persistent inflammatory back pain, unexplained heel or joint inflammation, and acute eye symptoms if they arise.
The diagnosis should also be reconsidered over time. A person may initially have undifferentiated back pain, then develop psoriasis, inflammatory bowel disease, uveitis, or clearer imaging changes. Longitudinal clinical records can be more valuable than repeating the unchanged HLA-B27 test.
Back pain requires urgent evaluation when it is accompanied by fever, unexplained weight loss, a history of cancer, major trauma, progressive weakness, or loss of bladder or bowel control. These warning signs point toward infection, fracture, cancer, or nerve compression rather than ordinary spondyloarthritis evaluation. HLA-B27 status should never delay assessment of those possibilities.
For routine follow-up after diagnosis, clinicians may use validated disease-activity questionnaires, functional measures, examination, inflammatory markers, and imaging only when it will change management. Repeating MRI on a fixed schedule is not always needed. Smoking cessation, regular movement, posture and mobility work, cardiovascular risk reduction, vaccination review, and screening for treatment complications can matter as much as the original genetic result.
A well-documented baseline evaluation can prevent confusion later. Recording the age at symptom onset, pattern of morning stiffness, response to movement, extra-articular features, family history, inflammatory markers, and imaging findings creates a clinical reference point. Future changes can then be judged against that record rather than against HLA-B27 status alone. This is especially useful when symptoms fluctuate, a treatment is changed, or a new manifestation such as uveitis, psoriasis, or bowel inflammation appears.
References
- Axial spondyloarthritis 2025 (Review)
- Axial Spondyloarthritis: A Review 2025 (Review)
- Exploring the Pathogenesis of Spondylarthritis beyond HLA-B27: A Descriptive Review 2024 (Review)
- Diagnosis and Treatment of Ankylosing Spondylitis 2024 (Review)
- ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update 2023 (Guideline)
Disclaimer
This article provides general information and cannot diagnose axial spondyloarthritis or interpret one person’s HLA-B27 result. A clinician should combine the test with symptoms, examination, inflammatory markers, imaging, ancestry, and alternative diagnoses. Seek prompt medical care for acute eye pain with redness or light sensitivity, or for severe back pain with fever or new neurologic symptoms.
